Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...

The heyday of digital health may not yet even be on the horizon, but investments in the field are certainly starting to hit the radar in the areas most likely to impact patients first --...

PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the company said that based on the results of dialogue with FDA, it will submit an NDA next quarter...